Several FDA-approved PARP-1 inhibitors, particularly Olaparib and Veliparib, have demonstrated cytoprotective and anti-inflammatory effects in preclinical models of non-oncological diseases such as lung inflammatory disorders, neurological disorders (e.g., stroke, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis), diabetes, and myocardial infarction [34,35,36]. This evidence concerns the gene PARP1 and multiple sclerosis.